Table 1 Baseline characteristics of NVAF patients compared between those on and not on OACs

Age (years)

64.32 ± 12.39

68.37 ± 10.70

67.38 ± 11.27

Male sex

528 (63.2%)

1452 (56.6%)

1980 (58.2%)

R₂CHA₂DS₂-VA score components

 Renal disease

335 (40.1%)

1259 (49.1%)

1594 (46.9%)

 History of heart failure

235 (28.1%)

810 (31.6%)

1045 (30.7%)

 Hypertension

467 (55.9%)

1861 (72.5%)

2328 (68.4%)

 Age ≥ 75 years

180 (21.5%)

799 (31.1%)

979 (28.8%)

 Diabetes mellitus

149 (17.8%)

690 (26.9%)

839 (24.7%)

 Previous stroke or TIA

54 (6.5%)

538 (21.0%)

592 (17.4%)

 Vascular disease

140 (16.7%)

441 (17.2%)

581 (17.1%)

 Age 50–74 years

562 (67.2%)

1650 (64.3%)

2212 (65.0%)

Antithrombotic medications

Antiplatelet

582 (69.6%)

308 (12.0%)

890 (26.2%)

 Aspirin

521 (62.3%)

263 (10.2%)

784 (23.0%)

 P2Y₁₂ inhibitors

119 (14.2%)

81 (3.2%)

200 (5.9%)

Anticoagulant

 Warfarin

0 (0.0%)

2338 (91.1%)

2338 (68.7%)

 Direct thrombin inhibitor

0 (0.0%)

82 (3.2%)

82 (2.4%)

 Factor Xa inhibitors

0 (0.0%)

145 (5.7%)

145 (4.3%)

R₂CHA₂DS₂-VA score

 0

43 (5.1%)

16 (0.6%)

59 (1.7%)

 1

145 (17.3%)

134 (5.2%)

279 (8.2%)

 2

150 (17.9%)

411 (16.0%)

561 (16.5%)

 3

161 (19.3%)

433 (16.9%)

594 (17.5%)

 4

114 (13.6%)

486 (18.9%)

600 (17.6%)

 5

103 (12.3%)

480 (18.7%)

583 (17.1%)

 6

69 (8.3%)

315 (12.3%)

384 (11.3%)

 7

36 (4.3%)

199 (7.8%)

235 (6.9%)

 8

10 (1.2%)

69 (2.7%)

79 (2.3%)

 9

4 (0.5%)

20 (0.8%)

24 (0.7%)

 10

1 (0.1%)

3 (0.1%)

4 (0.1%)

CHA₂DS₂-VA score

 0

48 (5.7%)

21 (0.8%)

69 (2.0%)

 1

205 (24.5%)

197 (7.7%)

402 (11.8%)

 2

223 (26.7%)

661 (25.8%)

884 (26.0%)

 3

183 (21.9%)

748 (29.2%)

931 (27.4%)

 4

95 (11.4%)

510 (19.9%)

605 (17.8%)

 5

57 (6.8%)

290 (11.3%)

347 (10.2%)

 6

20 (2.4%)

104 (4.1%)

124 (3.6%)

 7

4 (0.5%)

31 (1.2%)

35 (1.0%)

 8

1 (0.1%)

4 (0.2%)

5 (0.1%)

R₂CHA₂DS₂-VA score

3.22 ± 1.97

4.15 ± 1.84

3.92 ± 1.92

CHA₂DS₂-VA score

2.42 ± 1.46

3.17 ± 1.63

2.98 ± 1.43